
Myriad and UHC Sign a 3-year Contract for the myRisk Hereditary Cancer Test
The molecular diagnostic testing company Myriad Genetics announced that it had signed a 3-year contract with UnitedHealthcare to make their myRisk cancer susceptibility test accessible to patients.
Myriad Genetics, Inc. (Nasdaq:MYGN)
Myriad's myRisk Hereditary Cancer test uses next-generation sequencing technology to evaluate 25 clinically significant hereditary cancer genes associated with eight major hereditary cancers including: breast, colon, ovarian, endometrial, pancreatic, prostate, gastric cancers and melanoma. The myRisk test has demonstrated in multiple clinical studies a significant increase in sensitivity by identifying over 50 percent more patients with deleterious mutations that place a patient at substantially greater lifetime risk for cancer.
"Myriad has been a pioneer in hereditary cancer testing for almost 20 years," said Mark Capone, president of Myriad Genetic Laboratories. "Through scientific research and innovation, Myriad is able to provide a significantly more comprehensive, next generation cancer test for hereditary cancer syndromes.
Source: Myriad Genetics
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.